Enhancement of antitumor immunity by CTLA-4 antisense oligonucleotides with CpG motif in mice
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2025.115648 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Kuo Qu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, College of Basic Medical Sciences, Jilin University, Changchun 130021, Jilin, People's Republic of China. Hauptthemen laut MEDLINE: Oligonucleotides, Antisense, CTLA-4 Antigen, Colonic Neoplasms, Melanoma, Experimental. Die Arbeit nennt 50 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is a critical immune checkpoint molecule that negatively regulates T-cell activation and immune responses. Antibodies blocking CTLA-4 enhance anti-tumor T-cell responses, making them effective cancer immunotherapeutics. However, the CTLA-4 antibodies can trigger significant immune-related adverse events (irAEs). These toxicities may arise in part from antibody-induced complement activation and antibody-dependent cell-mediated cytotoxicity (ADCC) toward normal cells. Here, we report the development of a non-antibody immune checkpoint inhibitor comprising a CTLA-4-targeting antisense oligonucleotide (ASO) incorporating CpG motifs (CpG-CTLA-4 ASO), designated as ISA2. Similar to CpG ODN, a toll-like receptor 9 (TLR9) agonist, ISA2 upregulates costimulatory molecules in both B cells and CD11c+ cells. Simultaneously, ISA2 significantly downregulates CTLA-4 expression in both CD4+ and CD8+ T cell populations. The dual immunomodulatory functions of CpG-CTLA-4 ASO-simultaneously providing costimulatory activation and CTLA-4 suppression-demonstrated remarkable therapeutic efficacy in murine melanoma and colon carcinoma models. The treatment outcomes included significant tumor growth inhibition, prolonged survival of tumor-bearing hosts and achievement of complete tumor regression in a subset of animals. The ISA2 represents a novel class of dual-functional immunotherapy with promising clinical applications. Unlike conventional CTLA-4 antibodies, this agent combines TLR9 agonism with CTLA-4 silencing in a single molecular entity, enabling simultaneous immune activation and checkpoint blockade. This innovative design offers several potential clinical advantages: (1) augmentation of tumor-specific T-cell responses through synergistic modulation of both innate and adaptive immunity; (2) potentially reduced antibody-dependent toxicity compared to conventional antibody-based CTLA-4 blockade therapies; and (3) enhanced delivery flexibility attributable to its favorable small-molecule properties.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, College of Basic Medical Sciences, Jilin University, Changchun 130021, Jilin, People's Republic of China.
- Department of Neonatology and Institute of Pediatrics, Children's Medical Center, First Hospital of Jilin University, Jilin University, Changchun 130021, Jilin, People's Republic of China; Department of Molecular Biolog…
- Department of Molecular Biology, College of Basic Medical Sciences, Jilin University, Changchun 130021, Jilin, People's Republic of China.
- Department of Molecular Biology, College of Basic Medical Sciences, Jilin University, Changchun 130021, Jilin, People's Republic of China. Electronic address: wangliy@jlu.edu.cn.
- Department of Immunology, College of Basic Medical Sciences, Jilin University, Changchun 130021, Jilin, People's Republic of China. Electronic address: ylyu@jlu.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Qu, K., Zhu, M., Lu, F., Zhu, T., Wang, T., Wang, L., & Yu, Y. (2025). Enhancement of antitumor immunity by CTLA-4 antisense oligonucleotides with CpG motif in mice. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115648
Vancouver
Qu K, Zhu M, Lu F, Zhu T, Wang T, Wang L, et al. Enhancement of antitumor immunity by CTLA-4 antisense oligonucleotides with CpG motif in mice. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115648
BibTeX
@article{Qu2025,
author = {Qu, Kuo and Zhu, Mengru and Lu, Feiyu and Zhu, Tong and Wang, Tingli and Wang, Liying and Yu, Yongli},
title = {Enhancement of antitumor immunity by CTLA-4 antisense oligonucleotides with CpG motif in mice},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2025.115648}
}
EUVIMED